UroGen Pharma's second quarter revenue nearly triples to $72.5 million, driven by strong ZUSDURI launch.

UroGen Pharma reported second quarter revenue of $72.5 million, a significant increase from $24.2 million in the prior-year period. The company posted a net loss of $0.28 per share, narrowing from a loss of $1.05 per share a year ago, fueled by the successful commercial launch of its new drug, ZUSDURI.

Key Highlights

• Newly launched ZUSDURI generated $50.4 million in net product revenue, representing 73% quarter-over-quarter growth.
• JELMYTO revenue was $22.0 million for the quarter; the company reaffirmed its full-year 2026 guidance range of $97 million to $101 million for the drug.
• UroGen increased its full-year 2026 operating expense guidance to a range of $260 million to $270 million to accelerate investment behind the strong ZUSDURI launch.